Browse drugs

… the condition where there is very limited T cell infiltration. TJ-CP3B is currently in development as a promising drug candidate for c…

…tors (e.g., Siglecs) to the immunological synapse. As a result, AbLecs enhanced antitumor immune responses in vitro and in vivo compar…

…or frequency of dosing.Conclusions Median time to ovulation for DMPA SC 104 mg of 212 days was similar to that of DMPA IM 150 mg of 183…

…zed to receive one of three treatment strategies: benralizumab, prednisolone, or a combination of both. IOS parameters, including inspirator…

…evidence of type-2 (T2) inflammation may not respond as well to OCS treatment compared with T2 high patients. 1 Aims To measure out…

…le-dose, double-blind, randomized, 4-way crossover studies with CHF1535 MS or HS were conducted in healthy volunteers, administered wit…

…es are shown in bold where p<0.05.Conclusion Patients receiving mepolizumab achieve early responses with significant overall symptom VAS an…

…nts to a novel anti-Thymic Stromal Lympopoetin (TSLP) biologic, Tezepelumab.Methods A retrospective, single-centre analysis was conducted o…

…of interest in 30 GCs—these contained 15 HER2+ GCs treated with trastuzumab and T-DXd subsequently. Analysis of patient-matched samples wit…

…mage quality across dose levels for 0.2 mm reconstructions with Hv56 (4.5), Hv64 (5), and Hv72 (5). In patient images, SNR and CNR d…

… event burden typically associated with Stage B HF.Conclusion A BNP threshold of ≥75 pg/mL more closely aligns Stage A patients wit…

…ccurred in-hospital and 4,367 post-discharge (mean 24.1 months).hs-TnT was measured in 27,254 patients (23.5%), declining from 29.5% t…